[Effect of the lipid-lowering agent, procetofen, on the makeup of human biliary lipids].
The effect of lipid-lowering treatment with procetofen (3 x 100 mg/day for 4-6 weeks) on the cholesterol saturation index (S.I.) of bile has been studied in 6 patients with type IIa or IIb pattern hyperlipoproteinemia. Compared with a control period with placebo, the S.I. was increased by more than 20% during active treatment in 2 patients. Oversaturation was reached in one case. In the other 4 patients, the changes did not exceed 20% of the control value. Thus, increased lithogenicity of bile does not appear to be a frequent effect of procetofen. A larger number of patients should therefore be studied to establish its true incidence.
D000328:Adult; D001646:Bile / Q000032:analysis / Q000187:drug effects*; D002784:Cholesterol / Q000032:analysis; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000032:analysis*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*; D013997:Time Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D011422:Propionates; D002784:Cholesterol
Influence de l'hypolipémiant procétofène sur la composition des lipides biliaires chez l'homme.